CanAssist Breast is a prognostic test developed by OncoStem which segregates early stage ER+/HER2- breast cancer patients as either ‘low-risk’ or ‘high-risk’ for distant cancer recurrence. CanAssist Breast is an immunohistochemistry based test which couples Artificial Intelligence to arrive at “risk of cancer recurrence”. Based on the risk, clinicians can decide on giving chemotherapy (for high-risk patients) or avoiding chemotherapy (for low-risk patients). For more information visit here
